AI-Antibody Discovery (mAIbe Collaboration)

About LenioBio

LenioBio is a private, platform-focused biotech company based in Aachen, Germany, that is commercializing its innovative ALiCE® (Almost Living Cell-Free Expression) technology. This eukaryotic, cell-free system enables the rapid production of complex, functional proteins—including challenging targets like GPCRs and antibodies—within 24 hours, without the need for cell line development. The company operates both a platform/product business model and a services arm (ALiCE® as a Service), targeting significant bottlenecks in biologics discovery and development. With strategic partnerships, non-dilutive funding from entities like the EU and CEPI, and a focus on scalability, LenioBio is positioned to disrupt traditional protein production workflows.